Israel Englander’s TScan Therapeutics TCRX Stock Holding History

Israel Englander’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	1,163,611 -296,674	-20%	-$316K	﹤0.01%	4230
2026 Q1	$1.47M	Buy	1,460,285 +1,056,667	+262%	+$1.13M	﹤0.01%	4120
2025 Q4	$404K	Sell	403,618 -62,468	-13%	-$90.4K	﹤0.01%	5080
2025 Q3	$848K	Sell	466,086 -164,052	-26%	-$291K	﹤0.01%	4740
2025 Q2	$914K	Buy	630,138 +398,963	+173%	+$576K	﹤0.01%	4478
2025 Q1	$319K	Buy	+231,175	New	+$500K	﹤0.01%	5070
2024 Q4	–	Sell	-48,672	Closed	-$242K	–	6451
2024 Q3	$242K	Buy	48,672 +20,783	+75%	+$125K	﹤0.01%	5327
2024 Q2	$163K	Sell	27,889 -364,226	-93%	-$2.87M	﹤0.01%	5212
2024 Q1	$3.11M	Buy	392,115 +293,033	+296%	+$1.84M	﹤0.01%	3330
2023 Q4	$578K	Buy	+99,082	New	+$454K	﹤0.01%	4554
2023 Q1	–	Sell	-19,244	Closed	-$31K	–	6846
2022 Q4	$31K	Buy	+19,244	New	+$47.2K	﹤0.01%	5927
2022 Q1	–	Sell	-12,276	Closed	-$55K	–	7485
2021 Q4	$55K	Sell	12,276 -17,964	-59%	-$130K	﹤0.01%	6452
2021 Q3	$252K	Buy	+30,240	New	+$280K	﹤0.01%	5945

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Israel Englander's TCRX Position: Q2 2026 in Review

Israel Englander reduced its TScan Therapeutics (TCRX) stake by 20% in Q2 2026, selling an estimated $316K and leaving 1,163,611 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #4230.

Israel Englander first reported a position in TCRX in Q3 2021 and has held it in 13 quarters since. The position peaked at $3.11M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Israel Englander held 1,163,611 shares of TScan Therapeutics worth $1.14M as of Q2 2026.
Israel Englander sold 296,674 TScan Therapeutics shares in Q2 2026, an estimated $316K.
TScan Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4230 holding.
Israel Englander first reported a position in TScan Therapeutics in Q3 2021 and has held it in 13 quarters since.
Israel Englander's TScan Therapeutics position peaked at $3.11M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.